Better Health for All

Athira Pharma's core business is dedicated to developing novel therapeutics for high unmet medical needs, including treatments for metastatic breast cancer, ALS, Alzheimer's, and Parkinson's diseases. While one lead candidate, fosgonimeton, failed to reach statistical significance in a 26-week Alzheimer's trial,

another candidate, lasofoxifene, demonstrated 13 months of progression-free survival in the ELAINE-2 trial for metastatic breast cancer. ATH-1105 has shown a favorable safety profile and was well-tolerated in a Phase 1 trial involving 80 healthy volunteers, with preclinical data suggesting improvements in ALS models. The company's product candidates have generally shown favorable safety and tolerability in clinical studies. However, Athira Pharma agreed to a $4 million settlement for failing to disclose allegations of scientific research misconduct by its former CEO, indicating a significant lack of transparency. R&D expenses were $4.3 million in Q1 2025, a substantial decrease from $21.2 million in Q1 2024. Concerns have also been raised regarding the ethical handling of clinical trials, specifically concerning data manipulation allegations and research attribution.

Fair Money & Economic Opportunity

Athira Pharma, Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases.

The company's core business does not involve lending, deposit services, or other financial products for consumers. Therefore, all KPIs related to financial services, customer financial data, lending practices, fees, and financial literacy initiatives are not applicable to its operations. While the company aims to develop therapies that can reach and positively impact everyone, including underserved dementia populations, this relates to healthcare access rather than financial inclusion or economic opportunity as defined by the rubric.

Fair Pay & Worker Respect

Athira Pharma underwent a significant restructuring, laying off 70% of its staff, affecting approximately 49 employees.

This action is expected to incur $2.8 million in costs and lead to $13.4 million in annual savings. Regarding employee sentiment, 67% of reviewers would recommend working at Athira to a friend, and 67% approve of CEO Mark Litton. Employees rated compensation and benefits at 3.7 out of 5 stars.

Fair Trade & Ethical Sourcing

No information was found in the provided articles regarding Athira Pharma, Inc.'s fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical sourcing clauses in contracts, share of spend on high-risk materials, or supplier diversity initiatives.

The articles primarily discuss scientific misconduct allegations and legal settlements unrelated to supply chain ethics.

Kind to Animals

Athira Pharma utilizes both *in vitro* methods, such as THP-1 cells and primary rat neurons, and *in vivo* animal models for preclinical data.

The company's preclinical research involves animal models, with studies indicating sample sizes like n=10 mice per group for ALS studies. While specific annual animal usage is not provided, the use of groups of animals for studies suggests a volume that is not negligible. The company's policy is not explicitly stated, but its use of animal models for preclinical research indicates a reliance on traditional animal assays.

No War, No Weapons

Athira Pharma, Inc. (now LeonaBio, Inc.) is a clinical-stage biopharmaceutical company focused on developing drug candidates for conditions such as metastatic breast cancer and amyotrophic lateral sclerosis (ALS).

The company's core business and operations, as described in the provided articles, do not involve arms manufacturing, military contracts, dual-use technologies with military applications, sales to embargoed regimes, or any other activities related to the 'No War, No Weapons' ethical value. Therefore, all KPIs are scored as N/A, indicating no defense or arms-related activities in its core business or operations.

Respect for Cultures & Communities

The company has one formal partnership, but it is with Sermonix Pharmaceuticals, Inc., which is not an indigenous or local community group.

Given the company's business model in biopharmaceutical research and clinical trials, formal partnerships with indigenous or local community groups are not applicable.

Safe & Smart Tech

Athira Pharma has not experienced cybersecurity incidents that have materially affected its business, and it utilizes the NIST Cybersecurity Framework, engages third-party cybersecurity experts for network security assessment and continuous system monitoring, and has established incident response processes.

The company enforces single sign-on or multi-factor authentication where supported. However, Athira Pharma settled for $4 million to resolve allegations of data manipulation by its former CEO, Leen Kawas, who falsified images in her doctoral dissertation and at least four research papers. These altered papers were referenced in NIH grant applications and a company patent. The company faces significant business risk due to its dependency on compliance with FDA cGMP regulations, with potential struggles in quality control and assurance, and non-compliance could lead to severe sanctions. While the company reports its cybersecurity risk management and governance process in its yearly 10-K filing, it does not explicitly state its compliance status with all relevant privacy regulations.